PRO MEDICUS

Pro Medicus posted record results for fiscal 2026 with revenue of 261.7 million AUD and adjusted EBIT of 196 million AUD, yielding an EBIT margin of almost 75%. Cash and financial assets amounted to about 250 million AUD, and the value of recurring five‑year contracts rose to 1.3 billion AUD. The company closed several large deals in North America and plans product launches in diagnostic reporting and digital pathology to support growth. Management is targeting currency‑adjusted revenue and EBIT growth of more than 30% for 2027; the stock reacted with a 12.4% premarket rise. » More on de.investing.com

Medicus Pharma discussed the results of the phase‑2 trial SKNJCT‑003 on SkinJect in a fireside chat, which showed a clinical clearance rate of 73% at day 57 with 200 µg doxorubicin versus 38% in the control group. The randomized, double‑blind study with 47 patients confirmed dose‑dependent effects; management answered questions live without recording. Despite the data, the stock has fallen sharply and shows high volatility; quarterly results will be released on March 30. » More on de.investing.com

Pro Medicus reported for H1 2026 record revenue of $124.8m (+28.4%) and profit after tax of $171.2m (including around $150m of unrealised gains from 4DMedical), adjusted EBIT of $90.7m with an EBIT margin of 72.6%. The debt‑free company increased the interim dividend by 28% to $0.32 and improved its liquidity position to $221.8m; it secured seven new contracts with a minimum volume of over A$280m, including a A$170m deal with University of Colorado Health. Pro Medicus emphasised growth in North America, strategic expansion in cardiology and digital pathology, and an “AI‑ready” platform. Despite the operational strength, the stock plunged about 19.7% to A$169.47, apparently due to investor concerns about the sustainability of the profit increase and a high valuation. » More on de.investing.com